Trevi Therapeutics (NASDAQ:TRVI) Now Covered by Cantor Fitzgerald

Analysts at Cantor Fitzgerald started coverage on shares of Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) in a note issued to investors on Tuesday, Marketbeat reports. The firm set an "overweight" rating and a $25.00 price target on the stock. Cantor Fitzgerald's price target would suggest a potential upside of 324.02% from the stock's current price. Cantor Fitzgerald also issued estimates for Trevi Therapeutics' FY2025 earnings at ($0.39) EPS and FY2026 earnings at ($0.47) EPS.

Several other research firms have also commented on TRVI. HC Wainwright initiated coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They set a "buy" rating and a $21.00 price objective for the company. Wall Street Zen cut Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. B. Riley reissued a "buy" rating and issued a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Raymond James Financial raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their target price for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of Trevi Therapeutics in a report on Tuesday, May 20th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Trevi Therapeutics currently has an average rating of "Buy" and a consensus target price of $20.88.

Trevi Therapeutics Trading Down 1.4%

NASDAQ:TRVI traded down $0.08 during trading hours on Tuesday, reaching $5.90. 993,025 shares of the company were exchanged, compared to its average volume of 1,420,604. The stock's 50-day moving average is $6.28 and its 200-day moving average is $5.39. The firm has a market cap of $691.54 million, a PE ratio of -13.10 and a beta of 0.46. Trevi Therapeutics has a twelve month low of $2.36 and a twelve month high of $7.48.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.04. As a group, research analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. grew its holdings in shares of Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after purchasing an additional 2,894 shares during the period. Raymond James Financial Inc. purchased a new position in Trevi Therapeutics during the fourth quarter worth about $49,000. Strs Ohio acquired a new position in Trevi Therapeutics in the 1st quarter valued at about $52,000. Squarepoint Ops LLC purchased a new stake in shares of Trevi Therapeutics in the 4th quarter valued at approximately $58,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Trevi Therapeutics in the 4th quarter valued at approximately $66,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.